WuXi AppTec (2359.HK) - The Certainties and the Uncertainties
As the benchmark company in China CRO/CDMO industry, WuXi AppTec is always the focus of investors. This insight mainly analyzed the certainties and...
261 Views
U.S. Equity Strategy: Market Still Susceptible
We remain concerned about the prospect for additional weakness for the broad market due to deterioration in several metrics that we often turn to...
430 Views
Frontage Holdings IPO: Risk-Reward Is Favourable at the Low-End of Price Range
Frontage Holdings (1521 HK) has launched its Hong Kong IPO at a price range of HK$2.55-3.20 per share to raise HK$1.27-1.60 billion ($160-200...
781 Views
Viva Biotech IPO: Just About Supporting the Low-End IPO Price Range
Viva Biotech Holdings (1873 HK) is a leading global contract research organisation (CRO). It has launched its IPO to raise net proceeds of HK$1,232...
683 Views
India Generic Drugs: Antitrust Suit Could Cost Billions
This Insight builds on our previous Insight, India Generic Drugs: US Antitrust Inquiry Widens by discussing estimated potential liabilities and...
793 Views